About 200 Pilot Whales Perish on Australian Beach

Pilot whales beached on Macquarie Harbour, in Tasmania HANDOUT AFP
Pilot whales beached on Macquarie Harbour, in Tasmania HANDOUT AFP
TT

About 200 Pilot Whales Perish on Australian Beach

Pilot whales beached on Macquarie Harbour, in Tasmania HANDOUT AFP
Pilot whales beached on Macquarie Harbour, in Tasmania HANDOUT AFP

About 200 pilot whales have perished after stranding themselves on an exposed, surf-swept beach on the rugged west coast of Tasmania, Australian rescuers said Thursday.

Just 35 of the approximately 230 beached whales are still alive, according to state wildlife services, who described a tough battle ahead to rescue survivors, said AFP.

Aerial images from the scene revealed dozens of glossy, black mammals strewn along Ocean Beach, stuck on the waterline where the frigid southern ocean meets the sand.

Locals covered some of the creatures with blankets and doused them with buckets of sea water to keep them alive until more help arrived.

"We have got about 35 surviving animals out on the beach and the primary focus this morning will be on the rescue and release of these animals," said state wildlife operations manager, Brendon Clark.

"Unfortunately we do have a high mortality rate on this particular stranding," he added.

"The environmental conditions, the surf out there on the exposed west coast, Ocean Beach, is certainly taking its toll on the animals."

Helpers usually wade into the water and use harnesses to float the mammals into deeper waters, but officials said a new technique will also be tested, using an aquaculture firm's mechanical aid.

From there a vessel will take them to deeper clearer waters to avoid a new stranding.

Two years ago nearby Macquarie Harbor was the scene of the country's largest-ever mass stranding, involving almost 500 pilot whales.

More than 300 pilot whales died during that stranding, despite the efforts of dozens of volunteers who toiled for days in Tasmania's freezing waters to free them.

Clark said the conditions of the latest stranding were tougher for the whales than two years ago, when the animals were in "much more sheltered waters".

Attention will also turn to the removal and disposal of carcasses, which often attract sharks.

- Distress signals -

Necropsies will be performed for clues as to why the whales beached, but scientists still do not fully understand why mass strandings occur.

Scientists have suggested pods could go off track after feeding too close to shore.

Pilot whales -- which can grow to more than six meters (20 feet) long -- are also highly sociable, so they may follow podmates who stray into danger.

That sometimes occurs when old, sick or injured animals swim ashore and other pod members follow, trying to respond to the trapped whale's distress signals.

Others believe gently sloping beaches like those found in Tasmania confuse the whales' sonar making them think they are in open waters.

The latest stranding came days after a dozen young male sperm whales were reported dead in a separate mass stranding on King Island -- between Tasmania and the Australian mainland.

State officials said that incident may have been a case of "misadventure".

In nearby New Zealand strandings are also common.

There, around 300 animals beach themselves annually, according to official figures and it is not unusual for groups of between 20 and 50 pilot whales to run aground.

But numbers can run into the hundreds when a "super pod" is involved -- in 2017, there was a mass stranding of almost 700 pilot whales.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”